- Home
- LPRO vs CCCC Comparison
LPRO vs CCCC Comparison
Compare LPRO & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPRO
- CCCC
- Stock Information
- Founded
- LPRO 2000
- CCCC 2015
- Country
- LPRO United States
- CCCC United States
- Employees
- LPRO N/A
- CCCC N/A
- Industry
- LPRO Finance: Consumer Services
- CCCC Biotechnology: Pharmaceutical Preparations
- Sector
- LPRO Finance
- CCCC Health Care
- Exchange
- LPRO Nasdaq
- CCCC Nasdaq
- Market Cap
- LPRO 252.9M
- CCCC 242.3M
- IPO Year
- LPRO N/A
- CCCC 2020
- Fundamental
- Price
- LPRO $1.88
- CCCC $2.46
- Analyst Decision
- LPRO Buy
- CCCC Strong Buy
- Analyst Count
- LPRO 7
- CCCC 4
- Target Price
- LPRO $2.83
- CCCC $8.50
- AVG Volume (30 Days)
- LPRO 772.4K
- CCCC 1.4M
- Earning Date
- LPRO 11-06-2025
- CCCC 11-06-2025
- Dividend Yield
- LPRO N/A
- CCCC N/A
- EPS Growth
- LPRO N/A
- CCCC N/A
- EPS
- LPRO N/A
- CCCC N/A
- Revenue
- LPRO $16,948,000.00
- CCCC $30,108,000.00
- Revenue This Year
- LPRO $306.78
- CCCC N/A
- Revenue Next Year
- LPRO $11.69
- CCCC N/A
- P/E Ratio
- LPRO N/A
- CCCC N/A
- Revenue Growth
- LPRO N/A
- CCCC N/A
- 52 Week Low
- LPRO $0.70
- CCCC $1.09
- 52 Week High
- LPRO $6.75
- CCCC $5.10
- Technical
- Relative Strength Index (RSI)
- LPRO 57.66
- CCCC 51.14
- Support Level
- LPRO $1.45
- CCCC $2.29
- Resistance Level
- LPRO $1.67
- CCCC $2.63
- Average True Range (ATR)
- LPRO 0.14
- CCCC 0.15
- MACD
- LPRO 0.04
- CCCC 0.00
- Stochastic Oscillator
- LPRO 97.49
- CCCC 63.07
About LPRO Open Lending Corporation
Open Lending Corp is engaged in providing automated lending services to financial institutions. The company offers loan analytics, risk-based pricing, risk modeling, and automated decision technology. Its Lenders Protection Program ("LPP") enables automotive lenders to make loans that are largely insured against, losses from defaults.
About CCCC C4 Therapeutics Inc.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.